November 21, 2016 - By Clifton Ray · 0 Comments
The stock of Vitae Pharmaceuticals Incorporated (NASDAQ:VTAE) registered an increase of 3.81% in short interest. VTAE’s total short interest was 1.26 million shares in November as published by FINRA. Its up 3.81% from 1.21 million shares, reported previously. With 4.06M shares average volume, it will take short sellers 0 days to cover their VTAE’s short positions. The short interest to Vitae Pharmaceuticals Incorporated’s float is 6.38%. The stock closed at $21 during the last session. It is down 212.04% since March 23, 2016 and is uptrending. It has outperformed by 208.18% the S&P500.
Vitae Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $605.95 million. The Firm is focused on discovering and developing small molecule drugs for diseases. It currently has negative earnings. It is engaged in developing a portfolio of product candidates through Contour, its structure drug discovery platform.
Insitutional Activity: The institutional sentiment decreased to 1.86 in 2016 Q2. Its down 0.06, from 1.92 in 2016Q1. The ratio fall, as 14 funds sold all Vitae Pharmaceuticals Inc shares owned while 11 reduced positions. 11 funds bought stakes while 37 increased positions. They now own 20.80 million shares or 5.46% more from 19.72 million shares in 2016Q1.
Moreover, Morgan Stanley has 0% invested in Vitae Pharmaceuticals Inc (NASDAQ:VTAE) for 8,182 shares. Franklin Street Advisors Nc reported 100,800 shares or 0.21% of all its holdings. Adage Capital Prtnrs Group Limited Co holds 0.1% or 3.40M shares in its portfolio. The Pennsylvania-based Vanguard has invested 0% in Vitae Pharmaceuticals Inc (NASDAQ:VTAE). Comml Bank Of America De accumulated 2,203 shares or 0% of the stock. Bridgeway Mngmt Inc holds 0.01% or 60,350 shares in its portfolio. Blackrock Fund Advsrs accumulated 1.05M shares or 0% of the stock. Moreover, Proshare Advsrs Limited Liability Com has 0% invested in Vitae Pharmaceuticals Inc (NASDAQ:VTAE) for 24,686 shares. The Texas-based Dimensional Fund Ltd Partnership has invested 0% in Vitae Pharmaceuticals Inc (NASDAQ:VTAE). Mufg Americas Hldgs has 566 shares for 0% of their US portfolio. Moreover, Wells Fargo & Mn has 0% invested in Vitae Pharmaceuticals Inc (NASDAQ:VTAE) for 8,437 shares. Balyasny Asset Management Limited Liability accumulated 301,086 shares or 0.02% of the stock. Trexquant Investment Lp holds 0.02% or 11,004 shares in its portfolio. New York State Common Retirement Fund has 12,100 shares for 0% of their US portfolio. Alliancebernstein Lp has invested 0% of its portfolio in Vitae Pharmaceuticals Inc (NASDAQ:VTAE).
Insider Transactions: Since September 14, 2016, the stock had 0 insider purchases, and 2 selling transactions for $22.41 million net activity. $21.37 million worth of shares were sold by ADAGE CAPITAL PARTNERS GP – L.L.C. on Wednesday, September 14. Hatfield Jeffrey S. had sold 50,000 shares worth $1.04M on Wednesday, September 14.
Out of 5 analysts covering Vitae Pharmaceuticals (NASDAQ:VTAE), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Vitae Pharmaceuticals has been the topic of 7 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The company was initiated on Friday, December 4 by Wells Fargo. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) earned “Buy” rating by Stifel Nicolaus on Thursday, March 17. The firm earned “Neutral” rating on Wednesday, September 21 by Piper Jaffray. The stock has “Market Perform” rating given by JMP Securities on Thursday, August 4. The company was downgraded on Thursday, September 15 by Wells Fargo. BMO Capital Markets initiated it with “Outperform” rating and $15 target price in Tuesday, April 12 report. Zacks upgraded the stock to “Sell” rating in Saturday, August 8 report.
More notable recent Vitae Pharmaceuticals Inc (NASDAQ:VTAE) news were published by: Fool.com which released: “Here’s Why Shares of Vitae Pharmaceuticals Inc Are Skyrocketing Today” on September 14, 2016, also 247Wallst.com with their article: “Could This Be the Big Comeback for Vitae Pharma?” published on March 17, 2016, 247Wallst.com published: “Vitae Pharma Prepares for Secondary Offering” on March 24, 2016. More interesting news about Vitae Pharmaceuticals Inc (NASDAQ:VTAE) were released by: Globenewswire.com and their article: “Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 …” published on November 18, 2015 as well as Globenewswire.com‘s news article titled: “Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors” with publication date: July 29, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray